MGC Pharmaceuticals Ltd’s (ASX:MXC) (OTCMKTS:MGCLF) (FRA:MGC) Roby Zomer speaks to Proactive's Andrew Scott following the publication of results in its phase II double blind clinical trial of ArtemiC in COVID-19 patients. The results show the treatment improved the clinical recovery of all infected patients compared with the those on a placebo. Zomer says the results now open potential market opportunities for the treatment to a wide range of diseases related to cytokine storm such as autoimmune diseases, inflammatory GI diseases, 'flu and chemotherapy patients.
MGC Pharma reports 100% success rate in its phase II ArtemiC study in COVID-19
Quick facts: MGC Pharmaceuticals Ltd
Price: 0.07 AUD
Market Cap: $156.02 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE